New Psychoactive Substances: A Potential Threat to Developing Countries

Document Type : Review Article(s)


1 Deputy Director, Department of Narcotics Control, Security Services Division, Ministry of Home Affairs, Bangladesh

2 Department of Microbiology and Hygiene, Bangladesh Agricultural University, Mymensingh-2202, Bangladesh



Background: New psychoactive substances (NPS) have become a global phenomenon, with over 134 countries and territories from 
all world regions reporting them. Since December 2021, governments, laboratories, and partner agencies have confirmed to the 
UNODC Early Warning Advisory (EWA) on NPS over 1124 substances. It is agreed that NPS control is one of the most challenging 
tasks for developing countries. Identifying the present and future threads of NPS is the most challenging task for law enforcement 
officials. The NPS research has a great impact on substance abuse policy-making and harm reduction strategies.

Methods: The data in this study were collected from the official websites of online journals, Google Scholar, UNODC, International 
Narcotics Control Board (INCB), and the Department of Narcotics Control (DNC). 

Findings: Among the eleven groups of NPS, synthetic cannabinoids and cathinones are the most prevalent and alarming in developing countries. In Bangladesh, NPS abuse has been first identified in 2016. Almost 60 countries adopted legislative solutions to manage NPS by 2021, with many using or amending existing legislation and others employing novel legal mechanisms. It is widely agreed by researchers that reducing the menace of NPS requires increased awareness among all stakeholders.

Conclusion: In the fight against the spread of NPS and its severe effects, law enforcement authorities and healthcare professional 
training must be seen as crucial aspects as well. Financing is also crucial for international organizations dealing with the NPS impact to continue fighting this war. The only way for policymakers to reduce NPS spread globally is through national and international cooperation. 


Mehedi Hasan:  (Google Scholar) (PubMed)

Shahjahan Ali Sarker:  (Google Scholar) (PubMed)


  1. Rychert M, Wilkins C. A critical analysis of the implementation of a legal regulated market for new psychoactive substances 
    (“legal highs”) in New Zealand. Int J Drug Policy. 2018;55:88-94. doi: 10.1016/j.drugpo.2018.02.014.
    2. Grafinger KE, Bernhard W, Weinmann W. Scheduling of new psychoactive substance the Swiss way: a review and critical analysis. Sci Justice. 2019;59(4):459-66. doi: 10.1016/j.scijus.2019.03.005.
    3. Peacock A, Bruno R, Gisev N, Degenhardt L, Hall W, Sedefov R, et al. New psychoactive substances: challenges for drug surveillance, control, and public health responses. Lancet. 2019;394(10209):1668-84. doi: 10.1016/s0140-6736(19)32231-7.
    4. Simão AY, Antunes M, Cabral E, Oliveira P, Rosendo LM, Brinca AT, et al. An update on the implications of new psychoactive 
    substances in public health. Int J Environ Res Public Health. 2022;19(8):4869. doi: 10.3390/ijerph19084869.
    5. Beydilli İ, Duyan M, Yılmaz F, Arslan ED, Korkmaz İ, Akçimen M, et al. Concomitant substance use increases the toxic effect of synthetic cannabinoid (bonsai): a prospective study. Acta Biomed. 2020;92(1):e2021006. doi: 10.23750/abm.v92i1.9989.
    6. Potts AJ, Cano C, Thomas SHL, Hill SL. Synthetic cannabinoid receptor agonists: classification and 
    nomenclature. Clin Toxicol (Phila). 2020;58(2):82-98. doi: 10.1080/15563650.2019.1661425.
    7. Costas-Insua C. Searching for New Cannabinoid CB1 Receptor-Interacting Proteins [thesis]. Spain, Madrid: 
    Universidad Complutense de Madrid; 2022.
    8. Alves VL, Gonçalves JL, Aguiar J, Teixeira HM, Câmara JS. The synthetic cannabinoids phenomenon: from structure 
    to toxicological properties. A review. Crit Rev Toxicol. 2020;50(5):359-82. doi: 10.1080/10408444.2020.1762539.
    9. Gonçalves JL, Alves VL, Aguiar J, Teixeira HM, Câmara JS. Synthetic cathinones: an evolving class of new psychoactive 
    substances. Crit Rev Toxicol. 2019;49(7):549-66. doi: 10.1080/10408444.2019.1679087.
    10. Soares J, Costa VM, Bastos ML, Carvalho F, Capela JP. An updated review on synthetic cathinones. Arch Toxicol. 
    2021;95(9):2895-940. doi: 10.1007/s00204-021-03083-3.
    11. Schifano F, Napoletano F, Arillotta D, Zangani C, Gilgar L, Guirguis A, et al. The clinical challenges of synthetic 
    cathinones. Br J Clin Pharmacol. 2020;86(3):410-9. doi: 10.1111/bcp.14132.
    12. Farré M, Papaseit E, Fonseca F, Torrens M. Addiction of hallucinogens, dissociatives, designer drugs and “legal highs”: 
    update on potential therapeutic use. In: el-Guebaly N, Carrà G, Galanter M, Baldacchino AM, eds. Textbook of Addiction 
    Treatment: International Perspectives. Cham: Springer; 2021. p. 259-79. doi: 10.1007/978-3-030-36391-8_19.
    13. Simonato P. Evaluating and Expanding Knowledge and Awareness of Health Professionals on the Consumption and Adverse Consequences of Novel Psychoactive Substances (NPS) Through Innovative Information Technologic Tools 
    [dissertation]. University of Hertfordshire; 2015. doi: 10.18745/th.16557.
    14. Cocchi V, Gasperini S, Hrelia P, Tirri M, Marti M, Lenzi M. Novel psychoactive phenethylamines: impact on genetic 
    material. Int J Mol Sci. 2020;21(24):9616. doi: 10.3390/ijms21249616.
    15. Zashidova GA. New psychoactive substances (NPS) and problems associated with their use in the world and in 
    Uzbekistan. In: Drug Cultures and Policy in Germany, Central Asia and China. Nomos Verlagsgesellschaft mbH & Co. KG; 
    2022. p. 69-92.
    16. Göl E, Çok I. New psychoactive substances in Turkey: narcotics cases assessed by the Council of Forensic Medicine between 2016 and 2017 in Ankara, Turkey. Forensic Sci Int. 2019;294:113-23. doi: 10.1016/j.forsciint.2018.11.003.
    17. Varì MR, Pichini S, Giorgetti R, Busardò FP. New psychoactive substances—synthetic stimulants. WIRES Forensic Sci. 
    2019;1(2):e1197. doi: 10.1002/wfs2.1197.
    18. Martins D, Garrido EM, Borges F, Garrido JM. Voltammetric profiling of new psychoactive substances: piperazine 
    derivatives. J Electroanal Chem (Lausanne). 2021;883:115054. doi: 10.1016/j.jelechem.2021.115054.
    19. Nthiga JN. An Investigation on and Isolation of Parasites That Infect Humans Associated with Catha Edulis Leaves Sold in 
    Selected Parts of Nairobi County, Kenya [dissertation]. Jomo Kenyatta University of Agriculture and Technology (JKUAT); 2022.
    20. Smith PR, Morley SR. New psychoactive substances. In: Rutty GN, ed. Essentials of Autopsy Practice: Reviews, Updates, and Advances. Cham: Springer; 2017. p. 59-85. doi: 10.1007/978-3-319-46997-3_4.
    21. Simão AY, Antunes M, Cabral E, Oliveira P, Rosendo LM, Brinca AT, et al. An update on the implications of new psychoactive substances in public health. Int J Environ Res Public Health. 2022;19(8):4869. doi: 10.3390/ijerph19084869.
    22. Corkery JM, Orsolini L, Papanti D, Schifano F, Miolo G, Stair JL, et al. Novel psychoactive substances (NPS) and 
    recent scenarios: epidemiological, anthropological and clinical pharmacological issues. In: Zloh M, Stair JL, Miolo G, eds. Light in Forensic Science: Issues and Applications. London: Royal Society of Chemistry; 2018. p. 207-557. doi:10.1039/9781788010344-00207. 
    23. Atumeyi AU, Ligom TT, Tivkaa JT. Intake and abuse of psychoactive substances and its relative consequences: a 
    review. Sci J Anal Chem. 2021;9(2):39-49. doi: 10.11648/j.sjac.20210902.12.

24. Ban TA. The role of serendipity in drug discovery. Dialogues Clin Neurosci. 2006;8(3):335-44. doi: 10.31887/DCNS.2006.8.3/tban.
25. Miyachi T, Ozaki A, Saito H, Sawano T, Tanimoto T, Crump A. Opioids: a ‘crisis’ of too much or not enough - or simply how 
rich you are and where you live? Eur J Pain. 2021;25(6):1181-94. doi: 10.1002/ejp.1767.
26. Braunstein MM. Mindful Marijuana Smoking: Health Tips for Cannabis Smokers. Rowman & Littlefield; 2022.
27. Nosseir O, Hadad C. Chemical Warfare Agents and Treatments. American Chemical Society; 2021.
28. Bishop-Freeman SC, Young KA, Aurelius MB, Hudson JS. Pediatric opioid fatalities: what can we learn for prevention? 
J Forensic Sci. 2021;66(4):1410-9. doi: 10.1111/1556-4029.14725.
29. Mazzoni IE. Contamination of sports supplements with novel psychoactive substances: an old history with new players. In: 
Rabin O, Corazza O, eds. Emerging Drugs in Sport. Cham: Springer; 2022. p. 17-32. doi: 10.1007/978-3-030-79293-0_2.
30. McClure-Begley TD, Roth BL. The promises and perils of psychedelic pharmacology for psychiatry. Nat Rev Drug 
Discov. 2022;21(6):463-73. doi: 10.1038/s41573-022-00421-7.
31. Ujváry I, Christie R, Evans-Brown M, Gallegos A, Jorge R, de Morais J, et al. DARK classics in chemical neuroscience: 
etonitazene and related benzimidazoles. ACS Chem Neurosci. 2021;12(7):1072-92. doi: 10.1021/acschemneuro.1c00037.
32. Sanabria E, Cuenca RE, Esteso M, Maldonado M. Benzodiazepines: their use either as essential medicines or as toxics substances. Toxics. 2021;9(2):25. doi: 10.3390/toxics9020025.
33. Rinaldi R, Bersani G, Marinelli E, Zaami S. The rise of new psychoactive substances and psychiatric implications: a 
wide-ranging, multifaceted challenge that needs far-reaching common legislative strategies. Hum Psychopharmacol. 
2020;35(3):e2727. doi: 10.1002/hup.2727.
34. Yeh HT, Chen HY, Liu SW, Weng TI, Fang CC, Yu JH, et al. Clinical presentations and predictors of in-hospital mortality 
in illicit drug users in the new psychoactive substances (NPS) endemic era in Taiwan. Toxics. 2022;10(7):386. doi:10.3390/toxics10070386.
35. Abdulrahim D, Bowden-Jones O. Textbook of Clinical Management of Club Drugs and Novel Psychoactive Substances: NEPTUNE Clinical Guidance. Cambridge University Press; 2022.
36. Varì MR, Mannocchi G, Tittarelli R, Campanozzi LL, Nittari G, Feola A, et al. New psychoactive substances: evolution in 
the exchange of information and innovative legal responses in the European Union. Int J Environ Res Public Health. 
2020;17(22):8704. doi: 10.3390/ijerph17228704.
37. James SP, Bondugji D. Gamma-Aminobutyric Acid (GABA) and the Endocannabinoids: Understanding the Risks and 
Opportunities. In: El-Shemy HA, ed. Natural Drugs from Plants. IntechOpen; 2021. doi: 10.5772/intechopen.99242.
38. World Health Organization (WHO). WHO Expert Committee on Drug Dependence: Forty-Fourth Report. WHO; 2022.
39. Vincenti F, Gregori A, Flammini M, Di Rosa F, Salomone A. Seizures of new psychoactive substances on the Italian 
territory during the COVID-19 pandemic. Forensic Sci Int. 2021;326:110904. doi: 10.1016/j.forsciint.2021.110904.
40. Orsolini L, Chiappini S, Corkery JM, Guirguis A, Papanti D, Schifano F. The use of new psychoactive substances (NPS) 
in young people and their role in mental health care: a systematic review. Expert Rev Neurother. 2019;19(12):1253-64. doi: 10.1080/14737175.2019.1666712.
41. Smith SW, Garlich FM. Availability and supply of novel psychoactive substances. In: Dargan PI, Wood DM, eds. 
Novel Psychoactive Substances. Boston: Academic Press; 2013. p. 55-77. doi: 10.1016/b978-0-12-415816-0.00003-1.